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accepted July 23,ypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the incidence of myocardial
infarction and death. Statin-induced lowering of low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular
morbidity and mortality. However, many individuals treated with statins do not achieve their target levels of LDL-C,
and thus, LDL-associated residual risk remains. Gain-of-function mutations of the proprotein convertase subtilisin/
kexin type 9 (PCSK9) are associated with hypercholesterolemia and increased risk of cardiovascular events.
Conversely, loss-of-function mutations are linked to low plasma LDL-C levels and a reduction of cardiovascular risk
without known unwanted effects on individual health. Experimental studies have revealed that PCSK9 reduces the
hepatic uptake of LDL-C by increasing the endosomal and lysosomal degradation of LDL receptors (LDLR). Low
intracellular cholesterol levels in response to statin treatment activate the sterol regulatory element-binding protein-
2 (SREBP-2), resulting in coexpression of LDLR and PCSK9. Although this self-regulatory mechanism contributes to
maintain cholesterol homeostasis preventing excessive cholesterol uptake, it may limit the therapeutic effect of
statins. A number of clinical studies have demonstrated that inhibition of PCSK9 alone and in addition to statins
potently reduces serum LDL-C concentrations. Moreover, experimental studies indicate that PCSK9 might accelerate
atherosclerosis by promoting inﬂammation, endothelial dysfunction, and hypertension by mechanisms independent
of the LDLR. Further research is needed to characterize the potential therapeutic and to rule out unwanted off-target
effects of PCSK9 inhibition. In this review we elucidate the role of PCSK9 in lipid homeostasis, highlight the impact
of PCSK9 on atherosclerosis, and summarize current therapeutic strategies targeting PCSK9. (J Am Coll Cardiol
2013;62:1401–8) ª 2013 by the American College of Cardiology FoundationSeidah et al. (1) ﬁrst characterized the novel proteinase
K-like subtilase, the proprotein convertase subtilisin/kexin
type 9 (PCSK9) (initially named neural apoptosis-regulated
convertase-1), which is expressed in hepatocytes, kidney
mesenchymal cells, intestinal ileum, and colon epithelia as
well as in embryonic brain telencephalon neurons. Shortly
thereafter, it was reported that single-point gain-of-function
mutations (ser127-to-arg and F216L) in the PCSK9 gene
located on chromosome 1p32.3 are associated with autosomal
dominant hypercholesterolemia (2). Experimental studies
established the central role of PCSK9 in regulation of
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2013.lysosomal degradation of hepatic low-density lipoprotein
receptor (LDLR), resulting in increased serum LDL
cholesterol (LDL-C) concentrations (3–5).
In the following years, additional gain-of-function
mutations of the PCSK9 gene were identiﬁed (6). Con-
versely, loss-of-function mutations of the PCSK9 gene were
discovered and linked to low plasma LDL-C levels and
a reduction of cardiovascular risk (7,8). In 2006, Zhao et al.
(9) reported a 32-year-old African American woman who
was compound heterozygous for loss-of-function mutations
in PCSK9 that disrupted synthesis (maternal allele) and
processing/secretion (paternal allele) of PCSK9. Despite the
absence of PCSK9 and a serum LDL-C concentration of
only 14 mg/dl, this college-educated woman is apparently
healthy. She is fertile and normotensive and has normal liver
and renal functions (9). In another study, an African woman
was described, who is homozygous for a nonsense variant
of PCSK9 (C679X) (10). Consistently, this woman had
a LDL-C concentration of 7 mg/dl without showing
medical problems caused by her very low LDL-C (10).
Thus, loss of function of PCSK9 results in substantial
hypocholesterolemia without known adverse effects on
individual health.
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EGF-A = epidermal growth
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PCSK9 Function
PCSK9 is the latest member of
the proprotein convertase family,
which currently consists of 9
members. The ﬁrst 8 of these
family members (proprotein con-
vertase-1 [PC1], PC2, furin, PC4,
PC5, paired basic amino acid
cleaving enzyme-4 [PACE4],PC7,
and subtilisin kexin isozyme-1)
cleave proteinprecursors of growth
factors, hormones, receptors, and
transmembrane transcription fac-
tors passing through the secretory
pathway (11). In contrast, PCSK9
enhances the endosomal and lyso-
somal degradation of cell surface
receptors that regulate lipidmetab-
olism in a nonenzymatic fashion
(12).
PCSK9 is synthesized as aFigure 1
Molecular Basis of PCSK9 Function and
Therapeutic Strategies Targeting PCSK9
(A) SREBP-2 induces coexpression of PCSK9 and LDLR. PCSK9 is synthesized as
a proprotein that undergoes intramolecular autocatalytic processing at
FAQ152YSIP site in the endoplasmic reticulum. Autocatalytic cleavage is required
for trafﬁcking PCSK9 from the endoplasmic reticulum to the secretory pathway.
The prodomain remains attached to the catalytic domain, preventing substrate
binding. 1. In the intracellular pathway, PCSK9 is sorted to lysosomes together
with LDLR promoting its degradation. 2. In the extracellular pathway, secreted
PCSK9 binds to the LDLR and is internalized in clathrin-coated endosomes,
resulting in the degradation of LDLR. This step requires expression of the auto-
somal recessive hypercholesterolemia adaptor protein. (B) Pharmacologic
approaches targeting PCSK9 synthesis or function are under development.
1) Antisense oligonucleotides or siRNAs inhibit PCSK9 protein expression by
speciﬁcally binding PCSK9 mRNA. 2) Mimetic peptides competitively bind to the
LDLR thereby preventing PCSK9-mediated degradation. 3) mAb inhibit PCSK9
function by speciﬁcally binding extracellular PCSK9. ARH ¼ autosomal recessive73-kDa zymogen of 692 amino acids and contains a signal
peptide, a prodomain (residues 31 to 152) and a catalytic
domain (residues 153 to 451) followed by a C-terminal
domain (residues 452 to 692) (13). PCSK9 undergoes
intramolecular autocatalytic processing at the FAQ152YSIP
site in the endoplasmic reticulum (ER) to form a 14-kDa
prodomain and a 63-kDa mature PCSK9 (14). After
cleavage, the prodomain remains closely attached to the
catalytic domain of PCSK9 blocking the substrate-binding
site (1,15–17). Autocatalytic cleavage is required for traf-
ﬁcking PCSK9 from the ER to the secretory pathway
(Fig. 1A) (18,19). In the extracellular pathway, PCSK9 is
secreted from the trans-Golgi network and internalized
together with the LDLR in clathrin-coated endosomes,
promoting degradation of LDLR (18). This step requires
binding of the cytosolic adaptor protein autosomal recessive
hypercholesterolemia (ARH) protein (20). In the intracellular
pathway, PCSK9 is directly sorted to lysosomes together with
LDLR, leading to its degradation (5,12). The catalytic
subunit of PCSK9 binds to the epidermal growth factor-like
repeat homology domain (EGF-A) in human LDLR
(17,21,22). Secretion of the prodomain together with a cata-
lytically inactive PCSK9 was shown to promote regular
degradation of LDLR, suggesting that secreted PCSK9 acts
as a chaperone rather than as a catalytic enzyme (21,23).hypercholesterolemia adaptor protein; ER ¼ endoplasmic reticulum; LDLR ¼ low-
density lipoprotein receptor; mAb ¼ monoclonal antibody; PCSK9 ¼ proprotein
convertase subtilisin/kexin type 9; siRNA ¼ small interfering RNA; SREBP-2 ¼
sterol regulatory element-binding protein.Role of PCSK9 in Lipid Homeostasis
Hepatic cholesterol metabolism. The major part of
circulating LDL-C is removed from the plasma by hepatic
uptake. This process is mediated via transmembrane LDLR
that internalizes bound LDL particles by endocytosis
(Fig. 1A) (24). After intracellular dissociation, the LDLRrecycles to the cell surface for reuse. Each LDLR is recycled
up to 150 times, indicating that slight changes in LDLR
availability by PCSK9-induced degradation might lead to
considerable changes in LDL-C (25). Low intracellular
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binding protein-2 (SREBP-2), leading to increased LDLR
gene expression, which enhances LDL-C clearance from
the circulation (3,26). Of note, SREBP-2 also induces
expression of PCSK9, leading to LDLR degradation, thus
limiting hepatic cholesterol uptake and increasing circulating
LDL-C (Fig. 2) (3,26). This highly coordinated expression
pattern contributes to a self-regulatory system preventing
excessive cholesterol uptake in order to preserve cholesterol
homeostasis.
Intestinal lipid metabolism. PCSK9 is also expressed in
the small intestine of mice and in human intestinal cells,
which play a central role in the regulation of lipid absorption
(27). In vitro, treatment of human intestinal epithelial cells
with recombinant PCSK9 enhanced cholesterol uptake,
reduced HMG-CoA reductase activity and thus cholesterol
synthesis, and increased protein expression of the cholesterol
transporters NPC1L1 and CD36 (28). In mice, gene inac-
tivation of PCSK9 signiﬁcantly reduced postprandial tri-
glyceridemia and enhanced clearance of chylomicrons (27).
In clinical studies, reduction of circulating PCSK9 by
treatment with a speciﬁc monoclonal antibody (mAb) was
associated with a reduction in serum triglyceride levels (29).
The clinical effects of intestinal PCSK9 modulation deserve
further investigation.
Impact of PCSK9 on Atherosclerosis
Hypercholesterolemia is a major cardiovascular risk factor
that accelerates the process of atherosclerotic plaque forma-
tion, thus increasing the incidence of stroke and myocardialFigure 2 SREBP-2-Mediated Coexpression of LDLR and PCSK9
Low intracellular cholesterol levels activate SREBP–2-mediated LDLR expression,
thereby increasing hepatic LDL-C uptake. Concurrently, SREBP-2 induces expres-
sion of PCSK9, which enhances hepatic LDLR degradation, thus preventing
excessive cholesterol uptake in order to preserve cholesterol homeostasis.
LDL-C ¼ low-density lipoprotein cholesterol; other abbreviations as in Figure 1.infarction. In mice fed a high-fat high-cholesterol diet, gene
inactivation of PCSK9 signiﬁcantly reduced aortic cholesteryl
esters, which were markedly increased by overexpression of
PCSK9, resulting in accelerated development of atheroscle-
rotic plaque (30). Comparable effects were observed in
apolipoprotein E (ApoE)-deﬁcient mice expressing null,
normal, or high levels of PCSK9 (30). Interestingly, circu-
lating LDL-C levels differed only slightly among these
animals, and it is unclear whether the slightly higher LDL-C
level found in transgenic mice is the only cause of the marked
increase in plaque burden observed in these animals (30). In
LDLR-deﬁcient mice expressing null, normal, or high levels
of PCSK9, the circulating cholesterol levels and aortic
accumulation of cholesteryl esters were similar to those of
wild-type mice, indicating that the harmful effect of PCSK9
on atherogenesis is mediated mainly by degradation of
LDLR (30). Transgenic mice expressing high levels of
PCSK9 and low levels of LDLR in the liver were less prone to
atherosclerosis than LDLR-deﬁcient mice, pointing to a key
role of a LDLR fraction that is resistant to PCSK9. This
fraction might be located intracellularly, as PCSK9 acts
primarily on the LDLR in the post-Golgi compartment and
on the cell surface. In addition, extrahepatic LDLR, which
might be less sensitive to circulating PCSK9, could
contribute to LDL-C uptake in transgenic mice (30).
Recently, it has been shown that PCSK9 is also expressed
in human atherosclerotic plaques (31). In vitro, PCSK9
secreted by vascular smooth muscle cells reduced LDLR
expression and LDL-C uptake of human and murine
macrophages, which might result in vascular lipid accumu-
lation and oxidation (31). Interestingly, a number of
experimental studies have identiﬁed additional mechanisms
by which PCSK9 might affect vascular biology (Table 1).
Inﬂammation. It is well established that atherosclerosis is
a chronic inﬂammatory disease (32). Systemic inﬂammation
is closely related to alterations in lipid metabolism. Although
interaction between metabolic and inﬂammatory pathways
is required for homeostasis, impaired crosstalk between
these pathways may also lead to metabolic dysregulation. In
mice, systemic inﬂammation induced by administration of
lipopolysaccharide led to increased expression of PCSK9
and decreased hepatic levels of LDLR, which was associated
with a signiﬁcant increase in circulating LDL-C (33).
Furthermore, small interfering RNA (siRNA)-mediated
knockdown of PCSK9 in human macrophages attenuated
inhibitor of nuclear factor kappa B alpha (IkB-a) degrada-
tion and nuclear factor kappa beta (Nf-kB) nuclear trans-
location, thereby increasing expression of proinﬂammatory
genes (34). Another proinﬂammatory mechanism might be
PCSK9-induced degradation of ApoE-receptor 2 (35),
which maintains an anti-inﬂammatory phenotype in
macrophages (36) and mediates antiapoptotic signaling (37).
In contrast, in HepG2 cells expressing the naturally occur-
ring gain-of-function mutation D374Y, microarray analysis
revealed that this mutation reduces expression of stress-
response genes and speciﬁc inﬂammatory pathways (38).
Table 1 LDL-Independent Effects of PCSK9
LDL-Independent
Effect Molecular Mechanism Ref. #
Inﬂammation In mice, lipopolysaccharide-induced inﬂammation is associated with enhanced expression
of PCSK9.
siRNA-mediated knockdown of PCSK9 in human macrophages attenuates oxLDL-induced
IkB-a degradation and Nf-kB nuclear translocation.
PCSK9 gain-of-function mutation D374Y reduces expression of stress response genes and
speciﬁc inﬂammatory pathways in HepG2 cells.
33
34
38
Endothelial
apoptosis
Knockdown of PCSK9 by siRNA reduces oxLDL-induced endothelial apoptosis by altering the
Bcl-2/Bax ratio and by inhibiting the activation of both caspase-9 and -3.
39
Blood pressure
regulation
Transfection of epithelial cells with PCSK9 reduces expression of cell surface ENaC. 41
Glucose
metabolism
In mice, gene inactivation of PCSK9 reduces insulin levels, resulting in glucose intolerance,
which is associated with malformation, apoptosis, and
inﬂammation of pancreatic islets.
43
Adipogenesis PCSK9 limits murine adipogenesis via regulation of adipose VLDLR levels. 45
Bax ¼ Bcl-2-associated X protein; Bcl-2 ¼ B-cell lymphoma 2; ENaC ¼ Epithelial (NAþ) channel; IkB-a ¼ inhibitor of nuclear factor kappaB alpha;
LDLR ¼ low-density lipoprotein receptor; Nf-kB ¼ nuclear factor kappaB; oxLDL ¼ oxidized LDL; PCSK9 ¼ proprotein convertase subtilisin/kexin
type 9; siRNA ¼ small interfering RNA; VLDLR ¼ very low-density lipoprotein receptor.
Urban et al. JACC Vol. 62, No. 16, 2013
Role of PCSK9 Inhibition in Dyslipidemia October 15, 2013:1401–8
1404Taken together, the effects of PCSK9 on inﬂammatory
pathways are of interest with regard to vascular biology and
their clinical consequences remain to be established.
Apoptotic cell death. Endothelial apoptosis and subse-
quent endothelial dysfunction plays a central role in the
pathogenesis of atherosclerosis. In human endothelial cells,
oxidized LDL (oxLDL)-induced apoptosis was associated
with increased expression of PCSK9. Knockdown of PCSK9
expression by siRNA signiﬁcantly reduced ox-LDL-induced
apoptosis by altering the Bcl-2/Bax ratio and by inhibiting
the activation of both caspase-9 and -3 (39). Gene silencing
of PCSK9 also decreased apoptotic cell death in cerebellar
granule neurons (37). Reduced expression of PCSK9 was
associated with increased levels of the ApoE-receptor 2.
Knockdown of the ApoE-receptor 2 reversed the protective
effect of PCSK9 RNA interference, indicating that proap-
optotic effects of PCSK9 might be due to altered ApoE-
receptor 2 function (37). In mice, ischemic stroke led to
an upregulation of PCSK9 in the ipsilateral lesion side of the
dentate gyrus (40). However, mouse behavior and lesion
volumes of PCSK9(/) mice did not signiﬁcantly differ
from those of wild-type mice. Moreover, PCSK9 expression
was not upregulated in the infarct or penumbra areas,
indicating that PCSK9 might not play a critical role in cell
death following ischemic stroke (40). Further in vivo studies
would be needed to distinguish the impact of PCSK9 on
apoptotic cell death in the cardiovascular system.
Blood pressure. Hypertension enhances the progression of
atherosclerosis. In epithelia expressing the epithelial (Naþ)
channel (ENaC), which regulates blood pressure by modu-
lating epithelial sodium reabsorption, transfection with
PCSK9 led to a signiﬁcant reduction of ENaC protein ex-
pression (41). Although ENaC protein was reduced at the
cell surface, PCSK9 did not affect ENaC endocytosis or
degradation of ENaC at the cell surface indicating a role of
PCSK9 in the regulation of ENaC trafﬁcking. Whetherthese cellular observations relate to blood pressure regulation
is not known.
Glucose tolerance. Diabetes is associated with accelerated
atherosclerosis (42). It is noteworthy that in pancreatic tissue
of PCSK9(/) mice, expression of LDLR is increased while
insulin levels are reduced, resulting in hyperglycemia and
glucose intolerance (43). Glucose intolerance was associated
with malformation, apoptosis, and inﬂammation of pan-
creatic islets, pointing to a potential regulatory role of
PCSK9 in normal pancreatic function. However, in clinical
studies inhibition of PCSK9 by mAb did not signiﬁcantly
alter glucose metabolism.
Adipose tissue metabolism. Obesity is related to increased
prevalence of atherosclerotic risk factors (44). Interestingly,
PCSK9(/) mice fed a normal chow diet for 6 months
accumulated approximately 80% more visceral adipose tissue
than wild-type mice (45). PCSK9 knockout was associated
with adipocyte hypertrophy, enhanced in vivo fatty acid
uptake, and ex vivo triglyceride synthesis. These effects were
also observed in PCSK9(/)/LDLR(/) mice, indicating
that degradation of the LDLR might not be involved. In
addition to the LDLR, PCSK9 interacts with the very low
density lipoprotein receptor (VLDLR), which is also
expressing the EGF-A domain (35). In fact, PCSK9(/)
mice showed signiﬁcantly higher cell surface expression of
VLDLR in perigonadal depots than wild-type mice.
Hepatic expression of PCSK9 in PCSK9(/) female mice
normalized both circulating PCSK9 levels and VLDLR
levels. In contrast, inactivation of hepatic PCSK9 in wild-type
females signiﬁcantly increased perigonadal VLDLR expres-
sion, suggesting that PCSK9 may limit visceral adipogenesis
via regulation of adipose VLDLR levels (45). However,
PCSK9(/) mice do not develop liver steatosis and are not
prone to obesity, suggesting that pharmacological inhibition
of PCSK9 will probably not adversely affect central obesity.
Ongoing clinical studies will address this point.
Table 2 Therapeutic Approaches Targeting PCSK9
Mechanism of Action Agent Company/Sponsor Phase
Monoclonal antibodies SAR236553/REGN727 Sanoﬁ/Regeneron 3
AMG 145 Amgen 3
RN316 Pﬁzer 2
RG7652 Roche/Genentech 2
LGT-209 Novartis 2
1D05-IgG2 Merck Pre-clinical
1B20 Merck Pre-clinical
J10, J16 Pﬁzer Pre-clinical
J17 Pﬁzer Pre-clinical
Adnectins BMS-962476 Bristol-Myers Squibb/Adnexus 1
Mimetic peptides EGF-AB peptide fragment Schering-Plough Pre-clinical
LDLR (H306Y) subfragment U.S. National Institutes of Health Pre-clinical
LDLR DNA construct U.S. National Institutes of Health Pre-clinical
Small-molecule inhibitors SX-PCK9 Serometrix Pre-clinical
TBD Shifa Biomedical Pre-clinical
Antisense oligonucleotides ISIS 394814 Isis Pre-clinical
SPC4061 Santaris-Pharma Pre-clinical
SPC5011 Santaris-Pharma 1 (terminated)
RNA interference ALN-PCS02 Alnylam 1
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Dyslipidemia is a major cardiovascular risk factor accountable
for 54% of population-attributable risk for myocardial
infarction (46). Statin-induced reduction in LDL-C by 1
mmol/l in 5 years is associated with a 12% decrease in all-
cause mortality and a 19% decrease in cardiovascular
mortality (47). However, a signiﬁcant number of individuals
with hypercholesterolemia do not achieve optimal levels of
LDL-C using currently available therapies (48,49). In
Europe and Canada, nearly 50% of hypercholesterolemic
subjects are not at their individual LDL-C target despite
treatment with statins (50). This fact might be explained by
an inadequate statin dosing, adverse effects under required
dose, statin-resistance, or insufﬁcient adherence. Therefore,
additional pharmacologic strategies to lower cholesterol are of
signiﬁcant interest (51).
In addition, statin treatment increases the expression of
PCSK9 in both normolipidemic and dyslipidemic subjects
(52,53). In the JUPITER (Justiﬁcation for theUse of statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin)
study, a randomized double-blind placebo-controlled trial,
treatment with 20 mg of rosuvastatin resulted in a 28%
increase in PCSK9 in men and 35% in women, respectively
(54). This phenomenon might be explained by the fact that
low intracellular cholesterol levels control gene expression of
both LDLR and PCSK9 via nuclear translocation of SREBP-
2 (55). Accordingly, missense mutations and loss-of function
mutations in the PCSK9 gene are associated with increased
statin response and hypocholesterolemia, pointing to the
potential beneﬁt of PCSK9 inhibition alone and its potentially
additive effect in combination with statins (56,57). Table 2
summarizes the pharmacologic approaches targeting PCSK9
synthesis or function that are currently under development.Mimetic peptides and adnectins. Mimetic peptides are
designed as competitive inhibitors that mimic the EGF-A
binding domain of the LDLR, which interacts with
PCSK9 (Fig. 1B). In HepG2 cells, a synthetic EGF-A
peptide that binds the LDLR, dose-dependently inhibits
PCSK9-mediated degradation of LDLR (58). The isolated
C-terminal domain of PCSK9 reduces PCSK9-mediated
degradation of LDLR in vitro and in mice (59). There-
fore, the use of short PCSK9 fragments that competitively
bind to the LDLR without causing its degradation repre-
sents an alternative approach.
Adnectins are genetically engineered target-binding
proteins comprising a scaffold of the human ﬁbronectin.
Adnectins have similarities with mAb but are smaller in size,
as they are single domain structures without disulﬁde bonds
(60). The adnectin BMS-962476 is currently tested in a
phase I trial (see Table 2).
Small-molecule inhibitors. A promising strategy could be
the development of small molecules, which can be admin-
istered orally. A pre-clinical trial of a small-molecule agent
has been announced; however, the approach seems chal-
lenging. First, the stability and potency of small molecules in
plasma is poor (12). Second, it is difﬁcult to develop
a molecule that targets the ﬂat and large binding interface of
LDLR and PCSK9 (61). Third, small molecules might
arbitrarily affect PCSK9 function at different levels
including intracellular processing, secretion, and interaction
with LDLR (62).
Gene Silencing. Alternative techniques to inhibit PCSK9
function relate to the use of either antisense oligonucleotides
or siRNAs targeting PCSK9 gene expression (Fig. 1B). In
mice fed a high-fat diet, intraperitoneal administration of
PCSK9-antisense oligonucleotides increased hepatic LDLR
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38% (63). Correspondingly, locked nucleic acid-antisense
oligonucleotides such as SPC5001 signiﬁcantly reduced
PCSK9 levels and increased hepatic LDLR expression,
resulting in lower circulating LDL-C levels in mice and
nonhuman primates (64,65). However, a dose-escalating
double-blind phase I trial with SPC5001 in healthy indi-
viduals and individuals with familial hypercholesterolemia
was prematurely terminated in 2011 for unknown reasons.
In addition to antisense oligonucleotides, intravenously
administered siRNAs targeting PCSK9 mRNA were shown
to effectively reduce circulating LDL-C levels by 50% to
70% in mice and rats and by 50% in nonhuman primates
(66). The injection of a PCSK9 siRNA (ALN-PCS)
resulted in a dose-dependent and durable reduction of
LDL-C by up to 50% relative to baseline and placebo and
a mean reduction of 41% (p <0.01) in 32 healthy individuals
with elevated baseline LDL-C (>116 mg/dl). Further
development and testing of the second-generation ALN-
PCS02, and of the subcutaneously administered ALN-
PCSsc were announced (67).
Monoclonal antibodies. The most promising strategy to
inhibit PCSK9-mediated degradation of LDLR seems to be
the use of mAb (Fig. 1B). In 2009, the ﬁrst mAb was
intravenously administered to cynomolgus monkeys and
resulted in an 80% reduction of LDL-C (68). In the
following years, a number of other mAb, such as 1D05-IgG2
(Merck), 1B20 (Merck); and J10, J16, and J17 (Pﬁzer) were
developed and successfully tested in mice and nonhuman
primates (Table 2). Several human mAb have entered clinical
phase 2 trials, including RN316 (Pﬁzer), LGT209 (Novar-
tis), and MPSK3169A (Genentech). AMG145 (Amgen)
and SAR236553/REGN727 (Sanoﬁ/Regeneron) are cur-
rently being evaluated in phase 3 trials.
In a phase 1 ascending single-dose study, AMG145
injected intravenously or subcutaneously reduced LDL-C by
up to 64% versus placebo in healthy individuals (p < 0.0001)
(69). In patients receiving a stable statin dose, AMG145
reduced circulating LDL-C by 75%, without report of
serious adverse effects. In the following 4 phase 2 trials, the
effect of AMG145 was investigated in patients with statin-
intolerance (70), in patients with heterozygous familial
hypercholesterolemia (71), or those with non-familial
hypercholesterolemia with (72) or without lipid-lowering
therapy (73). These trials examined the effect of different
doses of AMG145 (70 to 420 mg) injected every 2 weeks or
every 4 weeks on circulating LDL-C levels. In summary,
subcutaneous administration of AMG145 every 2 weeks led
to signiﬁcant and sustained reduction of LDL-C, ranging
from 41% to 66%. No treatment-related serious adverse
events were reported (74). The effects of AMG145 on clinical
outcomes are characterized in the large phase 3 PROFICIO
study program. The most important trial is the FOURIER
(Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects With Elevated Risk) study testing the
effects of AMG145 on cardiovascular events in >20,000patients with prior myocardial infarction or stroke, with at
least 1 major or 2 minor coronary risk factors, and fasting
LDL-C level 70 mg/dl or non-high-density lipoprotein
cholesterol level of 100 mg/dl taking stable maximal
tolerated doses of atorvastatin with or without ezetimibe (75).
The mAb SAR236553/REGN727 was compared to
placebo in several clinical studies in healthy volunteers with
LDL-C concentration >100 mg/dl, in patients with
heterozygous familial hypercholesterolemia or nonfamilial
hypercholesterolemia receiving stable doses of atorvastatin,
and in patients with nonfamilial hypercholesterolemia (76).
These studies were followed by multicenter, double-blinded,
phase 2 trials including patients with hypercholesterolemia
(LDL-C >100 mg/dl) despite treatment with stable doses
of atorvastatin (29), patients with heterozygous familial
hypercholesterolemia receiving stable doses of statins with or
without ezetimibe (77), and patients with hypercholester-
olemia (LDL-C >100 mg/dl) despite treatment with ator-
vastatin (78). Consistently, SAR236553/REGN727 therapy
resulted in reductions of LDL-C levels of 50% to 70%. The
effects of SAR236553/REGN727 on clinical events are further
assessed in the large phase 3 ODYSSEY study program in-
cluding the ODYSSEY OUTCOME trial in 18,000 patients
who recently suffered an acute coronary syndrome (74).
Conclusions and Future Perspectives
PCSK9 plays a central role in the regulation of cholesterol
homeostasis by increasing the degradation of hepatic
LDLR, resulting in hypercholesterolemia, a major cardio-
vascular risk factor for atherosclerosis. In clinical studies,
inhibition of PCSK9 in addition to statin treatment potently
reduced serum LDL-C. Ongoing studies will evaluate the
impact of inhibiting PCSK9 on the incidence of cardio-
vascular events. Experimental studies report that PCSK9
might accelerate atherosclerosis by mechanisms beyond
degradation of hepatic LDLR. These pre-clinical experi-
mental data suggest that further research is needed to
understand the potential beneﬁcial therapeutic effects and to
rule out unwanted off-target effects of PCSK9 inhibition.
Speciﬁcally, it is of interest to systematically investigate the
role of PCSK9 for the pathogenesis of diabetes, obesity,
hypertension, inﬂammation, and endothelial dysfunction.
These studies will help to further characterize and under-
stand the function of PCSK9 in human health and disease.
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